Mumbai-based Piramal Pharma Limited, a leading global pharmaceuticals and wellness company, in conjunction with the 2025 SelectUSA Investment Summit, has committed to a $90 million investment plan towards expanding two of the company's US facilities.
These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply, and in line with Piramal Pharma's overall belief in the value and benefits of US-based innovation. In both cases, Piramal Pharma is making brownfield expansions to existing sites, financed by bank loans and internal accruals, which is the fastest, lowest risk, and most economical way to add new capacities to the US market.
Piramal Pharma's Lexington, Kentucky, facility specialises in sterile compounding, liquid filling, and lyophilisation for sterile injectable drug products. The site's expansion which includes 24,000 square feet of manufacturing space and a new laboratory adds commercial-scale manufacturing that will enable the efficient scale-up of clients' injectable drug products. Key additions include a new filling line, two commercial-size lyophilisers, a special capping machine, and an external vial washer. The facility is expected to be completed and online by late 2027.
While Piramal Pharma's Riverview, Michigan site, has earned a reputation as an industry leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs) over the past 50+ years. Here, the company is adding a commercial-scale suite specifically for the development and manufacturing of payload-linkers. These high potency APIs are used in the development of antibody-drug conjugates (ADCs) and other bioconjugate drugs. The new payload-linker suite is expected to be operational before the end of 2025.
"Since its inception, Piramal Pharma Ltd has invested $570 million in its US drug development and manufacturing capabilities," said Peter DeYoung, Chief Executive Officer, Global Pharma. "The US is our largest market, where we currently employ approximately 750 people. Expanding the capacities and offerings in these two plants in the US, along with the prior major investments made in our Sellersville PA drug product facility, and our inhalation anesthesia drug substance and drug product facility in Bethlehem PA, will support our customers who value our offerings in an onshore setting."
